Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTLAFZV)

• DTT Name: AMP-activated protein kinase (AMPK) DTT Info
• Gene Name: PRKAA1

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acadesine	DM1RMF5	Diabetic complication	5A2Y	Phase 3	[1]
ENERGI-F701	DMMIHSO	Alopecia	ED70	Phase 2	[2]
Imeglimin	DMMQFG2	Diabetic complication	5A2Y	Phase 2	[3]
MB-11055	DM3RBJW	Fatty liver disease	DB92.Z	Phase 2	[4]
O-304	DMXM34I	Type 2 diabetes	5A11	Phase 2	[5]
PXL-770	DMNSRY7	Non-alcoholic fatty liver disease	DB92	Phase 2	[6]
IM156	DM4MY9C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenformin	DMQ52JG	Diabetic complication	5A2Y	Withdrawn from market	[8]

8 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[9]
4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol	DML5NF6	Discovery agent	N.A.	Investigative	[10]
Debio-0930	DMFTNAP	Metabolic disorder	5C50-5D2Z	Investigative	[11]
Dorsomorphin	DMKYXJW	Discovery agent	N.A.	Investigative	[10]
OSU-53	DMQPJXT	Triple negative breast cancer	2C60-2C65	Investigative	[12]
PMID23639540C13a	DMLXOAQ	Discovery agent	N.A.	Investigative	[13]
SU 6656	DMF1P6W	Discovery agent	N.A.	Investigative	[14]
TG-1022	DMSG0TL	Obesity	5B81	Investigative	[11]

References

• [1] Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44.
• [2] Clinical pipeline report, company report or official report of Energenesis Biomedical.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
• [4] Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72.
• [5] Clinical pipeline report, company report or official report of Betagenon.
• [6] Clinical pipeline report, company report or official report of Poxel SA.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59.
• [9] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [10] The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular a... Bioorg Med Chem Lett. 2010 Nov 15;20(22):6394-9.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1540).
• [12] A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab. 2015 May;100(5):E748-56.
• [13] Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
• [14] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.